Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin in children and adolescents with ASD
NCT01256060Phase 2Completed
- Start
- Nov 2010
- Primary completion
- Mar 2013
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD). Primary endpoints: Maximum Tolerated Dose at 12 weeks and Serious Adverse Events at 24 weeks. Started Nov 2010; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01256060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256060.